(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.32%) $91.87
@ $1.190
Issued: 14 Feb 2024 @ 15:54
Return: -47.16%
Previous signal: Feb 14 - 13:31
Previous signal:
Return: 3.48 %
Live Chart Being Loaded With Signals
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score...
Stats | |
---|---|
Today's Volume | 617 892 |
Average Volume | 1.91M |
Market Cap | 40.10M |
EPS | $-0.110 ( 2023-11-14 ) |
Next earnings date | ( $-0.0800 ) 2024-06-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.700 |
ATR14 | $0.00100 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-24 | Icahn School Of Medicine At Mount Sinai | Buy | 9 360 374 | Ordinary Shares |
2023-11-20 | Coste Catherine | Buy | 95 000 | Employee Stock Option (right to buy) |
2023-11-20 | Levangie Daniel J | Buy | 95 000 | Employee Stock Option (right to buy) |
2023-11-20 | Parikh Chirag R. | Buy | 95 000 | Employee Stock Option (right to buy) |
2023-11-20 | Mills Christopher | Buy | 95 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
84.22 |
Last 27 transactions |
Buy: 12 713 670 | Sell: 1 641 743 |
Volume Correlation
Renalytix AI plc Correlation
10 Most Positive Correlations | |
---|---|
PUCK | 0.925 |
NVCN | 0.921 |
TWLV | 0.92 |
TWCB | 0.92 |
KSICU | 0.919 |
GXII | 0.918 |
OVID | 0.917 |
UBFO | 0.916 |
TBLA | 0.915 |
KVSA | 0.914 |
10 Most Negative Correlations | |
---|---|
AMGN | -0.943 |
NAKD | -0.921 |
CYTO | -0.921 |
AHPI | -0.913 |
HCAQ | -0.909 |
PROC | -0.905 |
LAWS | -0.905 |
THMA | -0.896 |
PCSA | -0.894 |
LSAQ | -0.892 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Renalytix AI plc Correlation - Currency/Commodity
Renalytix AI plc Financials
Annual | 2023 |
Revenue: | $3.40M |
Gross Profit: | $701 000 (20.60 %) |
EPS: | $-1.120 |
FY | 2023 |
Revenue: | $3.40M |
Gross Profit: | $701 000 (20.60 %) |
EPS: | $-1.120 |
FY | 2022 |
Revenue: | $2.97M |
Gross Profit: | $918 000 (30.91 %) |
EPS: | $-1.560 |
FY | 2021 |
Revenue: | $1.49M |
Gross Profit: | $633 000 (42.45 %) |
EPS: | $-0.860 |
Financial Reports:
No articles found.
Renalytix AI plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators